ACTG A5090

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。认知障碍是HIV感染的常见后遗症，可发展为痴呆。HIV痴呆的基本特征是致残性认知障碍，通常伴有运动功能障碍和行为改变。两项关于selegiline的初步研究已经证明了低剂量selegiline的安全性，并表明在hiv相关认知障碍患者的言语记忆和精神运动速度表现方面有所改善。本研究的目的是确定hiv相关认知障碍患者长期使用STS的安全性，并评估STS治疗hiv相关认知障碍的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cognitive impairement is a common sequela of HIV infection that can progress to dementia. The essential features of HIV dementia are disabling cognitive impairment, usually accompanied by motor dysfunction and behavioral change. Two pilot studies of selegiline have demonstrated safety for low dose selegiline and have suggested improvement in verbal memory and psychomotor speed performance in patients with HIV-associated cognitive impairment. The objective of this study is to determine the safety of long-term use of STS in subjects with HIV-associated cognitive impairment and to assess the efficacy of STS in the treatment of HIV-associated cognitive impairment.